Veradermics (MANE) vs Supernus (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Supernus is the larger company by market cap ($5.94 billion vs $5.04 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MANE | SUPN |
|---|---|---|
| Share price | $119.52 | $28.61 |
| Market cap | $5.04B | $5.94B |
| 1-day change | -3.92% | +0.92% |
| YTD return | — | -42.43% |
| 1-year return | — | -36.87% |
| 5-year return | — | -6.53% |
| Forward P/E | — | 7.15 |
| EPS (TTM) | $-3.89 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | $-70.00M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $156.63 | $42.81 |
| 52-week low | $32.00 | $25.92 |
| Distance from 52-week high | -23.69% | -33.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +56.74% | +89.23% |
| Average volume | 738.22K | 2.77M |
| Shares outstanding | 42.20M | 207.72M |
| Employees | 51 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Supernus
SUPN stock →Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
MANE vs SUPN FAQ
Which is bigger, Veradermics or Supernus?
Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.04B for Veradermics (MANE).
Are Veradermics and Supernus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.